The triglyceride-to-high density lipoprotein cholesterol ratio in overweight Korean children and adolescents

Dong-Yoon Yoo, MD1, Yu Sun Kang, MD2, Eun Byul Kwon, MD1, Eun-Gyong Yoo, MD, PhD1

1Department of Pediatrics, CHA Bundang Medical Center, CHA University, Seongnam, 2Department of Pediatrics, CHA Gumi Medical Center, Gumi, Korea

Purpose: The triglyceride-to-high-density lipoprotein cholesterol (TG/HDL-C) ratio has recently been reported as a biomarker of cardiometabolic risk in obese children and adolescents. The purpose of this study is to describe the TG/HDL-C ratio and related factors in overweight and normal weight Korean children and to evaluate whether the high TG/HDL-C ratio is associated with insulin resistance in overweight children and adolescents.

Methods: Data from 255 overweight (aged 8.7±2.0 years) and 514 normal weight (aged 8.9±1.8 years) children and adolescents were evaluated. Glucose, insulin, total cholesterol (TC), HDL-C and TG levels were measured after overnight fasting, and the TG/HDL-C ratio, non–HDL-C and the homeostasis model assessment of insulin resistance (HOMA-IR) were calculated.

Results: The TG/HDL-C ratio was higher in overweight group compared to normal weight group (P<0.001). Among overweight children and adolescents, alanine aminotransferase (P=0.018), non–HDL-C (P<0.001), and HOMA-IR (P=0.004) were different between the TG/HDL-C ratio tertile groups. The prevalence of elevated HOMA-IR was increased with increasing TG/HDL-C ratio tertiles (P for trend=0.003). On regression analysis adjusted for age and sex, the BMI (β=0.402, P=0.001) and TG/HDL-C ratio (β=0.251, P=0.014) were independently associated with HOMA-IR (adjusted R2=0.324). The TG/HDL-C ratio of 2.0 or more showed higher sensitivity (55.6%) and specificity (72.9%), when compared to TC (≥200 mg/dL), non–HDL-C (≥145 mg/dL), and LDL-C (≥130 mg/dL) for identifying overweight children with elevated HOMA-IR.

Conclusion: The TG/HDL-C ratio is independently associated with insulin resistance in overweight children and adolescents, and it can be useful in identifying those at higher cardiometabolic risk.

Keywords: Dyslipidemia, Obesity, Hypertriglyceridemia, Insulin resistance, Child, Adolescent

Introduction

With increased consumption of high-calorie food and sedentary life styles, the prevalence of obesity in children has increased worldwide1. Childhood obesity is associated with cardiovascular risk factors including dyslipidemia, hypertension, and insulin resistance2,3. Dyslipidemia is related with the initiation and progression of atherosclerosis4. Atherosclerosis begins in childhood with fatty streaks, and progress to fibrous plaques, which might rupture and cause ischemic organ damage, in adulthood5. It is important to identify those with higher risk for atherosclerosis to prevent its long-term complications and premature mortality.

Triglycerides (TGs) are major components of triglyceride-rich lipoproteins (TRLs) which
are synthesized from the liver and intestinal enterocytes. Epidemiologic studies have demonstrated that elevated TGs are independently associated with increased cardiovascular risk. Recent genetic studies also provide evidence that TGs and TRLs are in the causal pathway of cardiovascular disease (CVD).

The triglyceride-to-high density lipoprotein cholesterol (TG/HDL-C) ratio was associated with insulin resistance and impaired glucose tolerance (IGT) in obese youths. The TG/HDL-C ratio was also suggested as a marker of endothelial dysfunction and structural vascular changes in obese children and adolescents. The aims of this study are (1) to describe the TG/HDL-C ratio and related factors in overweight vs. normal weight Korean children, (2) to evaluate whether the high TG/HDL-C ratio is associated with insulin resistance in overweight children.

Materials and methods

1. Participants

Data from 769 Korean children (255 overweight children, aged 8.7±2.0 years, and 514 normal weight children, aged 8.9±1.8 years) who visited CHA Bundang Medical Center between March 2014 and April 2015, were retrospectively evaluated. Children with chronic disorders, including diabetes mellitus and thyroid disorders, or those under growth hormone treatment, were excluded. Glucose, insulin, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and TG levels were measured after overnight fasting, and the TG/HDL-C ratio, non–HDL-C (HDL-C subtracted from TC) were calculated. Insulin resistance was measured by homeostasis model assessment of insulin resistance (HOMA-IR) in a subgroup of children (32 normal weight and 74 overweight children). This study was approved by Institutional Review Board of CHA Bundang Medical Center and informed consent was waived (CHAMC 2016-08-014).

Table 1. Clinical and metabolic characteristics of normal weight and overweight children

| Characteristic          | Normal weight (n=514) | Overweight (n=255) | P-value |
|-------------------------|----------------------|--------------------|---------|
| Female sex              | 418 (81.3)           | 178 (70.8)         | 0.106   |
| Age (yr)                | 8.9±1.8              | 8.7±2.0            |         |
| BA–CA                   | 0.9±2.2              | 0.9±3.2            | 0.824   |
| Height SDS              | 0.3±1.0              | 0.9±1.0            | <0.001  |
| BMI SDS                 | -0.02±0.8            | 1.7±0.5            | <0.001  |
| Waist circumference     | 69.1±7.1 (n=25)      | 79.2±10.0 (n=77)   | <0.001  |
| SBP (mm/Hg)             | 104.3±8.8 (n=30)     | 109.7±9.7 (n=127)  | 0.006   |
| DBP (mm/Hg)             | 58.0±8.5 (n=30)      | 61.3±9.8 (n=127)   | 0.092   |
| AST (IU/L)              | 24.3±5.6             | 24.5±8.3           | 0.681   |
| ALT (IU/L)              | 14.9±6.5             | 22.6±20.1          | <0.001  |
| Glucose (mg/dL)         | 95.8±6.8             | 96.9±6.9           | 0.027   |
| Total cholesterol (mg/dL)| 170.3±29.8           | 172.3±29.0         | 0.053   |
| HDL-C (mg/dL)           | 58.6±11.2            | 53.0±11.3          | <0.001  |
| Non-HDL-C (mg/dL)       | 111.7±27.9           | 119.3±27.6         | <0.001  |
| Triglycerides (mg/dL)   | 74.2±36.3            | 100.0±26.7         | <0.001  |
| LDL-C (mg/dL)           | 96.0±26.4            | 100.1±26.7         | 0.117   |
| TG/HDL ratio            | 1.4±0.9              | 2.0±1.9            | <0.001  |
| HOMA-IR                 | 2.4±1.6 (n=32)       | 3.3±2.3 (n=74)     | 0.067   |

Values are presented as number (%) or mean±standard deviation.

BA–CA, bone age minus chronological age; BMI SDS, body mass index standard deviation scores; SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG/HDL, triglyceride-to-high density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance.
3. Statistical analysis

Data are described as means±standard deviations for continuous variables. Categorical variables were expressed as proportion (%) and were compared by chi-square test. First, we examined the differences in metabolic parameters between normal weight and overweight group. Between-group differences were tested using independent sample t-test. Second, TG/HDL-C ratio tertile groups were divided, and 1-way analysis of variance with Bonferroni post hoc test was used to compare variables between groups. To describe the trend of metabolic parameters with increasing TG/HDL-C ratio, P for trend was calculated from TG/HDL-C ratio tertile groups by analysis of covariance.

Table 2. Prevalence of abnormal metabolic parameters in normal weight vs. overweight children

| Variable               | Normal weight (%) | Overweight (%) | P-value |
|------------------------|-------------------|----------------|---------|
| Central obesity*       | 20.0              | 84.4           | <0.001  |
| Glucose ≥100 mg/dL     | 27.6              | 35.7           | 0.220   |
| Total cholesterol ≥200 mg/dL | 11.9          | 17.3           | 0.410   |
| HDL-C <40 mg/dL        | 3.7               | 13.2           | <0.001  |
| Non–HDL-C ≥145 mg/dL  | 9.1               | 16.1           | 0.004   |
| Hypertriglyceridemia†  | 13.8              | 31.8           | <0.001  |
| LDL-C ≥130 mg/dL       | 8.8               | 12.2           | 0.137   |

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

*Waist circumference ≥90th percentile. †TG ≥130 mg/dL for ≥10 years of age or ≥100 mg/dL for <10 years of age.

Table 3. Metabolic parameters of overweight children according to tertiles of TG/HDL-C ratio

| Characteristic                       | TG/HDL-C ratio tertile | P-value |
|--------------------------------------|------------------------|---------|
|                                      | <1.17 (n=84)           |         |
|                                      | ≥1.17, <2.0 (n=81)     |         |
|                                      | ≥2.0 (n=90)            |         |
| Female sex                           | 51 (60.7)              |         |
|                                      | 59 (72.8)              |         |
|                                      | 68 (75.6)              |         |
| Age (yr)                             | 8.3±1.8                |         |
|                                      | 8.9±2.2                |         |
|                                      | 9.0±1.9                |         |
| Height SDS                           | 0.8±1.2                |         |
|                                      | 0.9±0.9                |         |
|                                      | 1.1±1.0                |         |
| BMI SDS                              | 1.6±0.5                |         |
|                                      | 1.7±0.5                |         |
|                                      | 1.7±0.6                |         |
| Waist circumference                  | 75.9±9.1 (n=30)        |         |
|                                      | 78.8±8.6 (n=24)        |         |
|                                      | 83.2±10.6 (n=22)       |         |
| SBP (mm/Hg)                          | 108.6±10.9 (n=39)      |         |
|                                      | 109.8±8.6 (n=41)       |         |
|                                      | 110.7±9.6 (n=47)       |         |
| DBP (mm/Hg)                          | 58.9±10.1 (n=39)       |         |
|                                      | 62.4±10.9 (n=41)       |         |
|                                      | 62.4±8.1 (n=47)        |         |
| AST (IU/L)                           | 23.7±6.1               |         |
|                                      | 24.0±6.5               |         |
|                                      | 25.8±10.9              |         |
| ALT (IU/L)                           | 18.9±11.8              |         |
|                                      | 21.2±10.6              |         |
|                                      | 27.2±29.6*             |         |
| Glucose (mg/dL)                      | 97.1±8.2               |         |
|                                      | 97.2±6.4               |         |
|                                      | 96.6±6.0               |         |
| Total cholesterol (mg/dL)            | 171.8±23.2             |         |
|                                      | 173.2±30.4             |         |
|                                      | 171.9±23.5             |         |
| HDL-C (mg/dL)                        | 61.5±11.1              |         |
|                                      | 53.3±7.3               |         |
|                                      | 44.8±8.3*              |         |
| Non–HDL-C (mg/dL)                    | 110.3±29.4             |         |
|                                      | 119.9±27.9*            |         |
|                                      | 127.1±23.1*            |         |
| Triglycerides (mg/dL)                | 50.5±10.8              |         |
|                                      | 81.0±14.8              |         |
|                                      | 152.1±76.1*            |         |
| LDL-C (mg/dL)                        | 100.2±28.8             |         |
|                                      | 103.7±27.7             |         |
|                                      | 96.7±23.6              |         |
| HOMA-IR                              | 2.7±1.3 (n=23)         |         |
|                                      | 2.5±1.6 (n=26)         |         |
|                                      | 4.5±3.2 (n=25)         |         |

P-values are presented as number (%) or mean±standard deviation. TG/HDL-C, triglyceride-to-high density lipoprotein cholesterol; BMI SDS, body mass index standard deviation scores; SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance.

*P<0.05 compared with 1st tertile group. †P<0.05 compared with 2nd tertile group.

The relationship between TG/HDL-C ratio and HOMA-IR in overweight children was evaluated by linear regression analysis after adjusting for age, sex, and BMI, as well as by Pearson correlation analysis. Because the HOMA-IR was not normally distributed, it was natural log transformed before correlation or regression analysis.

We also calculated the sensitivity and the specificity of each metabolic parameter for identifying high HOMA-IR in overweight children. The sensitivity was calculated by the proportion of children having high HOMA-IR who were correctly identified by the metabolic parameters, and the specificity was measured by the proportion of children without high HOMA-IR who were correctly screened by the metabolic parameters.

The IBM SPSS Statistics ver. 20.0 (IBM Co., Armonk, NY, USA) was used for all statistical analysis. A P-value of <0.05 was considered significant.

Results

1. Clinical characteristics of participants

Table 1 shows the characteristics of normal weight and overweight children. The systolic blood pressure (P=0.006), alanine aminotransferase (ALT) (P<0.001), and glucose (P=0.027) level was significantly increased in overweight children compared to normal weight children. Overweight children showed lower HDL-C (P<0.001), and higher non–HDL-C (P<0.001) and TG (P<0.001) levels than normal weight children. The TG/HDL-C ratio was also higher in overweight
group compared to normal weight group (2.0±1.9 vs. 1.4±0.9, \(P<0.001\)) (Table 1).

The prevalence of hypo-HDL-cholesterolemia (13.2% vs. 3.7\%, \(P<0.001\)), high non–HDL-C (16.1\% vs. 9.1\%, \(P<0.001\)), and hypertriglyceridemia (31.8\% vs. 13.8\%, \(P<0.001\)) was increased in overweight children compared to normal weight children (Table 2).

2. Trend of metabolic parameters according to TG/HDL–C ratio tertiles in overweight children

Table 3 describes the metabolic parameters of overweight children according to tertiles of TG/HDL-C ratio. BMI SDS showed no significant differences between the TG/HDL-C ratio tertile groups. However, ALT was higher in the third tertile group compared to the first and second tertile groups (\(P=0.006\) and 0.049 vs. first and second tertile group, respectively). Non-HDL-C level was lower in the first tertile group compared to second and third tertile group (\(P=0.020\) and \(P<0.001\) vs. second and third tertile group, respectively). The HOMA-IR was significantly higher in the highest tertile group when compared to the first and second tertile groups (\(P=0.008\) and \(P=0.002\) vs. first and second tertile group, respectively). The prevalence of high HOMA-IR increased with increasing TG/HDL-C ratio tertiles (\(P\) for trend=0.003).

3. Association between TG/HDL–C ratio and HOMA-IR in overweight children

The TG/HDL-C ratio correlated with HOMA-IR in overweight children (r=0.282, \(P=0.016\)). On regression analysis adjusted for age and sex, the BMI (\(\beta=0.402\), \(P=0.001\)) and TG/HDL-C ratio (\(\beta=0.251\), \(P=0.014\)) were independently associated with log transformed HOMA-IR (adjusted \(R^2\) of the model=0.324).

4. Sensitivity and specificity of metabolic parameters for identifying high HOMA–IR in overweight children

The TG/HDL-C ratio (\(\geq2.0\)) showed higher sensitivity (55.6\%) and specificity (72.9\%) for identifying overweight children with high HOMA-IR when compared to TC (\(\geq200\) mg/dL), non–HDL-C (\(\geq145\) mg/dL), and LDL-C (\(\geq130\) mg/dL). The specificity of high TG/HDL-C was better than that of hypertriglyceridemia in identifying overweight children with high HOMA-IR (72.9\% vs. 64.2\%, Table 4).

**Discussion**

Our study showed strong association between the TG/HDL-C ratio and the parameter of insulin resistance. The TG/HDL-C ratio was higher in overweight children than normal weight children, and the prevalence of high HOMA-IR was increased with increasing TG/HDL-C ratio tertiles in overweight children. The BMI and TG/HDL-C ratio were independently associated with HOMA-IR after adjusting for age and sex in overweight children.

Elevated TG levels have been known as a biomarker of cardiovascular risk, but the specific role of TGs has been controversial until recently. Recent genetic evidence from mutational analysis, genome wide association studies, and Mendelian randomization studies suggest that TGs and TRLs play a pathogenic role in atherosclerosis, rather than simply being a biomarker. In a meta-analysis, mutation in lipoprotein lipase that results in high TG levels increased the risk of ischemic heart disease nearly fivefold.

LDL-C has been the primary target to reduce cardiovascular risk, but recent studies show high residual risk among patients treated with statins. In fact, the most prevalent pattern in patients presenting with CVD event is characterized by elevated TG, decreased HDL-C, and normal to mildly elevated LDL-C, the profile commonly seen in individuals with insulin resistance and metabolic syndrome.

Lipoproteins must enter into the intima of arteries to cause atherosclerosis. Small dense LDL particles are more atherogenic, and the LDL particle size and the total LDL particle number, rather than routinely measured LDL-C levels, are more important. TRLs are a key determinant of heterogeneity of LDL size and plasma TG level shows strong inverse relationship with LDL particle size. It was also reported that TG/HDL-C ratio and non–HDL-C can identify overweight youth with atherogenic LDL particles.

Non–HDL-C reflects the cholesterol content in all potential atherogenic lipoproteins, including LDL-C, VLDL remnants, and chylomicron remnants. It can also be measured from nonfasting samples. The non–HDL-C was reported to be more effective for CVD prediction than LDL-C especially when TGs are elevated, and recent guidelines recommend that non–HDL-C should be the target in the management of cardiovascular risk.

Overweight children had higher systolic blood pressure, ALT, glucose, non–HDL-C and TG levels in our study. The earliest stages and progression of atherosclerosis are influenced by dyslipidemia, hypertension, smoking, obesity, and diabetes mellitus. Controlling these risk factors should be beneficial for the prevention of atherosclerosis progression. The earlier the
primary prevention begins, the better the result. Pediatricians should be involved in the prevention and control of these risk factors in children and adolescents.

Pacifio et al. suggested that TG/HDL-C ratio help identifying children at high risk for structural vascular change and metabolic derangement. The odds ratio of central obesity, insulin resistance, high high-sensitivity C-reactive protein, nonalcoholic fatty liver disease, metabolic syndrome, and elevated carotid artery intima-media thickness (cIMT) values were increased significantly, as TG/HDL-C ratio tertiles increased. Manco et al. reported that TG/HDL-C ratio ≥2.2 was significantly associated with IGT in children and adolescents, and the TG/HDL-C ratio, rather than TG level, can be used to identify those with at risk of IGT. Our result also showed independent association between the TG/HDL-C ratio and HOMA-IR after adjusting for age, sex and BMI.

The TG/HDL-C ratio may also predict insulin resistance mediated organ damage. Di Bonito et al. analyzed data from 5,505 children who were divided by non–HDL-C (≥130 mg/dL) or TG/HDL-C ratio (≥2.2). The odds ratios for insulin resistance, high blood pressure, metabolic syndrome, liver steatosis, increased cIMT, and left ventricular hypertrophy, were higher in children with high TG/HDL-C ratio compared to those with non–HDL-C, suggesting that the TG/HDL-C ratio identify individuals with atherogenic dyslipidemia, cardiometabolic risk, and preclinical signs of organ damage.

The prevalence of hypertriglyceridemia (TG≥150 mg/dL) was 21.7% in obese Turkish children, and 21.5% in overweight Korean children. In the present study, the prevalence of hypertriglyceridemia (TG≥130 mg/dL for ≥10 years of age or ≥100 mg/dL for <10 years of age) was 13.8% in normal weight group, and 31.8% in overweight group. Although hypertriglyceridemia is very common in overweight or obese children, TC, and non–high-density lipoprotein cholesterol (non–HDL-C) are commonly used screening tools for identifying children with dyslipidemia, and TG levels are less commonly measured in children.

In our study, TC and non–HDL-C were not sensitive to identify overweight children with increased insulin resistance. Recent guidelines recommend universal screening for dyslipidemia by nonfasting TC or non–HDL-C between age 9 and 11 years, however, targeted screening by the measurement of fasting lipid profile is recommended in children with BMI ≥95th percentile or adolescents with BMI ≥85th percentile, as well as those with family history of dyslipidemia or premature CVD.

It is not always easy to obtain fasting blood samples from children, and especially TG levels have high within-person variability. Recent data shows that nonfasting as well as fasting serum TGs are independently associated with cardiovascular risk. Postprandial TRLs are considered particularly proatherogenic, and studies suggested that nonfasting TGs are superior to fasting TGs as a cardiovascular risk predictor. The practice of measuring fasting TG levels has been questioned recently.

Di Bonito et al. used the TG/HDL-C ratio cutoff of 2.2 or higher based on the 75th percentile of 5,505 children including 4,417 obese children. The cut point of TG/HDL-C used in the studies by Pacifio et al. was 1.98 or higher, defined by the cutoff of the highest tertile among 548 children including 391 overweight/obese children. In our study, we defined high TG/HDL-C ratio by TG/HDL-C ≥2.0, according to the cut point of the highest tertile among 255 overweight children.

Limitation of our study is small sample size, especially the waist circumference, blood pressure and HOMA-IR was measured only in a subgroup of participants, and that the insulin resistance was measured by HOMA-IR, not by more accurate method.

In conclusion, the TG/HDL-C ratio is independently associated with insulin resistance in overweight children and adolescents. Our results support that TG levels should be included in screening obese children and adolescents at higher cardiometabolic risk.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**References**

1. Han JC, Lawlor DA, Kimm SY. Childhood obesity. Lancet 2010;375:1737-48.
2. Elmaoğulları S, Tepe D, Uçaktürk SA, Karaca Kara F, Demirel F. Prevalence of dyslipidemia and associated factors in obese children and adolescents. J Clin Res Pediatr Endocrinol 2015;7:228-34.
3. Lobstein T, Baur L, Uauy R; IASO International Obesity TaskForce. Obesity in children and young people: a crisis in public health. Obes Rev 2004;5 Suppl 1:1-104.
4. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998;338:1650-6.
5. McGill HC, McMahan CA, Gidding SS. Are pediatricians responsible for prevention of adult cardiovascular disease? Nat Clin Pract Cardiovasc Med 2009;6:10-1.
6. Boullart AC, de Graaf J, Stalenhoef AF. Serum triglycerides and risk of cardiovascular disease. Biochim Biophys Acta 2012;1821:867-75.
7. Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol 2016;118:138-45.
8. Manco M, Grugni G, Di Pietro M, Balsamo A, Di Candia S, Morino GS, et al. Triglycerides-to-HDL cholesterol ratio as screening tool for impaired glucose tolerance in obese children and adolescents. Acta Diabetol 2016;53:493-8.
9. Giannini C, Santoro N, Caprio S, Kim G, Lartaud D, Shaw M, et al. The triglyceride-to-HDL cholesterol ratio:
association with insulin resistance in obese youths of different ethnic backgrounds. Diabetes Care 2011;34:1869-74.

10. de Giorgis T, Marcovechio ML, Di Giovanni I, Giannini C, Chiavaroli V, Chiarella F, et al. Triglycerides-to-HDL ratio as a new marker of endothelial dysfunction in obese prepubertal children. Eur J Endocrinol 2013;170:173-80.

11. Musso C, Graffigna M, Soutelo J, Honfi M, Ledesma L, Miksztowicz V, et al. Cardiometabolic risk factors as apolipoprotein B, triglyceride/HDL-cholesterol ratio and C-reactive protein, in adolescents with and without obesity: cross-sectional study in middle class suburban children. Pediatr Diabetes 2011;12(3 Pt 2):229-34.

12. Pacifico L, Bonci E, Andreoli G, Romaggioli S, Di Miscio R, Lombardo CV, et al. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutr Metab Cardiovasc Dis 2014;24:737-43.

13. Moon JS, Lee SY, Nam CM, Choi JM, Choe BK, Seo JW, et al. 2007 Korean National Growth Charts: review of developmental process and an outlook. Korean J Pediatr 2008;51:1-25.

14. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128 Suppl 5:S213-56.

15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.

16. Benuck I. Point: The rationale for universal lipid screening and treatment in children. J Clin Lipidol 2015;9(Suppl): S93-100.

17. Vilela BS, Vasques AC, Cassani RS, Forti AC, Pareja JC, Tambascia MA, et al. The HOMA-Adiponectin (HOMA-AD) closely mirrors the HOMA-IR index in the Screening of Insulin Resistance in the Brazilian Metabolic Syndrome Study (BRAMS). PLoS One 2016;11:e0158751.

18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.

19. Wittrup HH, Tybaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999;99:2901-7.

20. Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keetch A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25.

21. Kavey RE, Mietus-Snyder M. Beyond cholesterol: the atherogenic consequences of combined dyslipidemia. J Pediatr 2012;161:977-9.

22. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 2011;5:105-13.

23. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002;43:1363-79.

24. Burns SF, Lee SJ, Arslanian SA. Surrogate lipid markers for small dense low-density lipoprotein particles in overweight youth. J Pediatr 2012;161:991-6.

25. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-333.

26. Di Bonito P, Valerio G, Grunigi G, Licenziati MR, Maffeis C, Manco M, et al. Comparison of non-HDL-cholesterol versus triglycerides-to-HDL-cholesterol ratio in relation to cardiometabolic risk factors and preclinical organ damage in overweight/obese children: the CARITALY study. Nutr Metab Cardiovasc Dis 2015;25:489-94.

27. Lim H, Xue H, Wang Y. Association between obesity and metabolic co-morbidities among children and adolescents in South Korea based on national data. BMC Public Health 2014;14:279.

28. Geoffrey R Simon, Cynthia Baker, Graham A Barden 3rd, Brown OW, Hardin A, Lessin HR, et al. 2014 recommendations for pediatric preventive health care. Pediatrics 2014;133:568-70.

29. van Wijk JP, Halkes CJ, De Jaegere PP, Plokker HW, Erkelens DW, Cabezas MC. Normalization of daytime triglycerideremia by simvastatin in fasting normo-triglyceridemic patients with premature coronary sclerosis. Atherosclerosis 2003;171:109-16.

30. Noordstaard BG, Benn M, Schnohr P, Tybaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308.

31. Nofer JR. Hyperlipidemia and cardiovascular disease: triglycerides - a revival of cardiovascular risk factor? Curr Opin Lipidol 2011;22:319-21.